almirall_logo

Kimberly Boldon, nurse practitioner:

Treatment testimonial video

Transcript

Open
Close

Hi, my name is Kimberly Bolden. I'm a nurse practitioner and owner of the Dermatology Center of Connecticut, located in Wallingford, Connecticut, and here is my experience.

I initially began prescribing KLISYRI® due to the fact that it's a short course, five-day treatment and patients really liked to have a new option.

Patients with actinic keratoses would benefit from treatment with KLISYRI®. I was keeping in mind that I treat a lot of patients who were very concerned about what they would look like during their course of treatment, especially when it comes to their face or scalp. And from what I've been told from the several patients who have tried KLISYRI®, they've been very pleased with the outcome. They said once the five-day course of treatment was over that they noticed a great improvement and that they really wouldn’t consider that they had any type of downtime involved in their course of treatment.

My advice to other dermatologists would be to give KLISYRI® a try. The majority of my patients who have given it a try were very, very pleased with their results. When treating a sensitive, vulnerable area such as the face, people are very hesitant to try new treatments and based on my experience and from what I have seen firsthand, KLISYRI® truly is the best option out there.

INDICATION

KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Ophthalmic Adverse Reactions

KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible

Local Skin Reactions

Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.

Please see full Prescribing Information.

Reference: 1. KLISYRI®. Prescribing information. Almirall, LLC.

KLISYRI® is a registered trademark of Almirall, LLC.
© 2005-2023
All Rights Reserved.
Almirall, LLC. 101 Lindenwood Drive, Ste 400, Malvern, PA 19355
US-TIRBA-2200036 05/2023

IMPORTANT SAFETY INFORMATION

INDICATION

KLISYRI is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis on the face or scalp.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Ophthalmic Adverse Reactions

KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.

Local Skin Reactions

Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.

Please see full Prescribing Information.

To report an adverse event or product complaint, call or email Medical Affairs and Customer Relations • Phone: 1-866-665-2782• Fax: 510-595-8183 •
Email: almirallmc@eversana.com